Application of Combined Therapy of Gankang Granule and Entecavir for Patients with Chronic Hepatitis B_West China Medical Journal

Authors：

 WangLin , ZhangHong , GaoFeng ,  FanHezhang

The Third Ward, Chengdu Public Health and Medical Center, Chengdu, Sichuan 610061, P. R. China;

Corresponding author：

FanHezhang, Email: fanzhangli@sina.com

Keywords：

Chronic hepatitis B; Treatment; Gankang granule; Entecavir

DOI：

10.7507/1002-0179.201600188

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the clinical efficacy of combined therapy of Gankang Granule and Entecavir for patients with chronic hepatitis B. Methods A total of 118 patients with chronic hepatitis B treated between January 2012 and January 2013 were randomly divided into treatment group (n=59) and control group (n=59). Patients in the treatment group were treated with Gankang Granule and Entecavir, while those in the control group were treated with Entecavir alone. Results Before treatment, there was no significant difference between the two groups in such liver fibrosis evaluation indexes as hyaluronic acid (HA), laminin (LN), procollagenⅢ(PCⅢ), and collegen typeⅣ(CⅣ) (P > 0.05). After treatment, the two groups had significant differences in HA, LN, PCⅢ, and CⅣ(P < 0.05). After 48 weeks of treatment, the alanine aminotransferase recovery rate was significantly different between the two groups (P < 0.05); but there was no significant difference in hepatitis B virus DNA negative conversion rate, hepatitis B e antigen negative conversion rate and hepatitis B e antibody seroconversion rate (P > 0.05). Forty-eight weeks after treatment began, 45 patients underwent liver biopsy which showed that liver fibrosis alleviation was significantly better in the treatment group than the control group (P < 0.05). Conclusions Gankang granule combined with antiviral drug Entecavir for chronic hepatitis B is better in protecting the liver and alleviating hepatic fibrosis than the sole Entecavir. The combined method is worthy of being promoted.

Citation： WangLin, ZhangHong, GaoFeng, FanHezhang. Application of Combined Therapy of Gankang Granule and Entecavir for Patients with Chronic Hepatitis B. West China Medical Journal, 2016, 31(4): 688-691. doi: 10.7507/1002-0179.201600188 Copy

1.	Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology, 2010, 51(2): 435-444.
2.	Lok AS. Hepatitis: long-term therapy of chronic hepatitis B reverses cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(4): 199-200.
3.	曾婷, 谢逸欣, 马丽. 恩替卡韦的药理毒理学研究[J]. 河北医学, 2012, 18(10): 1421-1423.
4.	中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 胃肠病学, 2011, 19(6): 351-366.
5.	中华医学会传染病与寄生虫病学会, 中华医学会肝病学分会. 病毒性肝炎防治方案[J]. 中华肝脏病杂志, 2000, 8(6): 324-329.
6.	World Health Organization. Guidelines for the Prevention. Care and treatement of persons with chronic hepatitis B infection[M]. Geneva: World Health Organization, 2015.
7.	李筠, 汤勃. 中药对慢性乙肝病毒复制的影响[J]. 世界华人消化杂志, 2000, 8(8): 945-946.
8.	何义华, 潘志恒, 李林, 等. 中药辨证治疗中重度慢性乙肝临床疗效对照分析[J]. 世界华人消化杂志, 2007, 15(28): 3006-3010.
9.	刘小明, 邱春艳, 丁新华, 等. 七五灵散调理慢性乙肝后40例[J]. 中国中医药现代远程教育, 2013, 11(24): 33.
10.	贺劲松, 周大桥, 童光东, 等. 补肾健脾胶囊治疗慢性乙肝病毒携带者的随机双盲实验[J]. 中国实验方剂学杂志, 2010, 16(6): 246-249.
11.	陆宁, 赵湖珊. 苦参素联合中药治疗慢性乙肝疗效观察[J]. 辽宁中医杂志, 2003, 30(1): 38-39.
12.	张开生, 王清霞. 丹参注射液联合复方甘草酸苷治疗慢性乙肝疗效观察[J]. 中国社区医师: 医学专业, 2010, 12(24): 120.
13.	唐茂华, 陈积, 饶丽萍. 恩替卡韦、阿德福韦、拉米夫定治疗慢性乙型肝炎的疗效比较[J]. 广东医学院学报, 2012, 30(2): 156-158.
14.	徐道振. 病毒性肝炎临床实践[M]. 北京: 人民卫生出版社, 2006: 335.
15.	Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J]. Lancet, 2013, 381(9865): 468-475.

1. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology, 2010, 51(2): 435-444.
2. Lok AS. Hepatitis: long-term therapy of chronic hepatitis B reverses cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(4): 199-200.
3. 曾婷, 谢逸欣, 马丽. 恩替卡韦的药理毒理学研究[J]. 河北医学, 2012, 18(10): 1421-1423.
4. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 胃肠病学, 2011, 19(6): 351-366.
5. 中华医学会传染病与寄生虫病学会, 中华医学会肝病学分会. 病毒性肝炎防治方案[J]. 中华肝脏病杂志, 2000, 8(6): 324-329.
6. World Health Organization. Guidelines for the Prevention. Care and treatement of persons with chronic hepatitis B infection[M]. Geneva: World Health Organization, 2015.
7. 李筠, 汤勃. 中药对慢性乙肝病毒复制的影响[J]. 世界华人消化杂志, 2000, 8(8): 945-946.
8. 何义华, 潘志恒, 李林, 等. 中药辨证治疗中重度慢性乙肝临床疗效对照分析[J]. 世界华人消化杂志, 2007, 15(28): 3006-3010.
9. 刘小明, 邱春艳, 丁新华, 等. 七五灵散调理慢性乙肝后40例[J]. 中国中医药现代远程教育, 2013, 11(24): 33.
10. 贺劲松, 周大桥, 童光东, 等. 补肾健脾胶囊治疗慢性乙肝病毒携带者的随机双盲实验[J]. 中国实验方剂学杂志, 2010, 16(6): 246-249.
11. 陆宁, 赵湖珊. 苦参素联合中药治疗慢性乙肝疗效观察[J]. 辽宁中医杂志, 2003, 30(1): 38-39.
12. 张开生, 王清霞. 丹参注射液联合复方甘草酸苷治疗慢性乙肝疗效观察[J]. 中国社区医师: 医学专业, 2010, 12(24): 120.
13. 唐茂华, 陈积, 饶丽萍. 恩替卡韦、阿德福韦、拉米夫定治疗慢性乙型肝炎的疗效比较[J]. 广东医学院学报, 2012, 30(2): 156-158.
14. 徐道振. 病毒性肝炎临床实践[M]. 北京: 人民卫生出版社, 2006: 335.
15. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J]. Lancet, 2013, 381(9865): 468-475.

West China Medical Journal

Application of Combined Therapy of Gankang Granule and Entecavir for Patients with Chronic Hepatitis B

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content